Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696017 | 1.00 | PARP1 (0.42) | PARP1TRPA1PNMTCD44MAOB | |
| SCHEMBL6488209 | 0.98 | PARP1 (0.41) | PARP1TRPA1PNMTCD44MAOB | |
| SCHEMBL7309901 | 0.92 | PARP1 (0.37) | PARP1TRPA1PNMTCD44MAOB | |
| Formic Acid SCHEMBL28778115 | 0.89 | PARP1 (0.35) | PARP1TRPA1 | |
| SCHEMBL4969401 | 0.78 | HTR2C (0.43) | PARP1TRPA1PNMTCD44MAOB | |
| SCHEMBL19540042 | 0.75 | TSHR (0.39) | TRPA1PNMTCD44MAOBHTR2C | |
| SCHEMBL5072285 | 0.71 | TRPA1 (0.44) | PARP1TRPA1PNMT | |
| SCHEMBL10152893 | 0.70 | PARP1 (0.39) | PARP1TRPA1PNMTCD44MAOB | |
| SCHEMBL28067377 | 0.69 | HTR2C (0.34) | TRPA1PNMTCD44MAOBHTR2C | |
| SCHEMBL4166260 | 0.68 | PNMT (0.37) | PNMTCD44MAOBHTR2CALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197228-A | Synthesis method of pyrazolone [ spiro ] dihydrophthalazine and 1,3-indenedione [ spiro ] dihydrophthalazine compounds | 河南师范大学 | 2022-10-18 | — | — | CN | claimed |
| CN-102953097-B | Electroplate liquid and electro-plating method | ROHM AND HAAS ELECTRONIC MATERIALS CO., LTD. (US) | 2016-01-13 | — | — | CN | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | claimed |
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | claimed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | claimed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | claimed |
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | claimed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| EP-0848000-B1 | Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor | TANABE SEIYAKU CO (JP) | 2002-06-12 | — | — | EP | claimed |
| WO-2000039100-A1 | PHTHALAZINE DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2000-07-06 | — | — | WO | claimed |
| EP-0848000-A1 | Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-17 | — | — | EP | claimed |
| CN-1032399-A | Method of immunity | UNILEVER NV (NL) | 1989-04-12 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | PARP1 1574/4885TRPA1 1740/4885PNMT 1643/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | PARP1 1574/4885TRPA1 1740/4885PNMT 1643/4885 |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | TYR, NOX5, NOXO1 | PARP1 4680/4885TRPA1 575/4885PNMT 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.